ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.34-2.61%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ORIC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ORIC — earnings miss
Dated 2026-08-03
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: The Phase 1b results can show whether enozertinib has activity in this group. ORIC had planned to share these results in 2H 2026.
Watch forORIC reports Phase 1b data in 2H 2026. The single-agent group has confirmed tumor responses.
Also watch forThe data show no confirmed tumor responses, or ORIC says the update has moved past 2H 2026.
Why it matters: The trial would test enozertinib in first-line EGFR atypical lung cancer. A start on time would move the program into a larger trial.
Supportive ifORIC announces that Redwood-1 has started by June 30, 2027.
Worry ifORIC delays the start beyond 1H 2027 or reports that it has not started by June 30, 2027.
Why it matters: ORIC reported $387.6 million in cash and investments at June 30, 2026. It said those funds could last into 2H 2028.
Worry ifAt a later report, ORIC cuts its cash runway estimate to before 2H 2028.
Less concerning ifORIC keeps its runway estimate at 2H 2028 or later and reports cash use in line with its plan.
Why it matters: ORIC's Q2 costs and net loss rose from a year earlier. The next report can show whether higher spending tracks trial work.
Worry ifOn November 12, ORIC reports Q3 operating costs above $45.3 million. It reports no added trial progress.
Less concerning ifQ3 operating costs are $45.3 million or less, or ORIC reports clear trial progress with higher costs.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$228 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $612 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,615 loss on $10,000 · 46.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Himalayas-1 is ORIC's first Phase 3 trial. Its progress and safety data can test the early results from smaller groups.
Watch forORIC reports that Himalayas-1 is enrolling near its planned pace, with no new major safety issue.
Also watch forORIC reports a trial delay, a pause in enrollment, or a new major safety issue.